SEARAINBOW(SZ:000503)2018-08-24 16:00Financial Performance - The company's operating revenue for the first half of 2018 was ¥22,353,316.37, a decrease of 72.53% compared to ¥81,386,088.54 in the same period last year[16]. - The net profit attributable to shareholders was -¥88,273,418.22, representing a decline of 10.36% from -¥79,989,820.85 year-on-year[16]. - The company reported a basic earnings per share of -¥0.0982, a decline of 10.36% from -¥0.0890 in the same period last year[16]. - The company's main business revenue for the reporting period was ¥22,353,316.37, a decrease of 72.53% compared to the previous year[48]. - The company reported a significant increase in cash received from other operating activities, amounting to ¥133,370,104.13, which is a 430.47% increase compared to ¥25,142,018.83 last year[50]. - The company’s R&D investment decreased by 65.41% year-on-year, amounting to ¥22,925,432.05, due to fewer projects compared to the previous year[48]. - The company reported a net cash inflow from the disposal of fixed assets of ¥75,637,272.68, a dramatic increase of 324,342.19% compared to ¥23,313.02 last year[50]. - The company reported a net loss for the current period of CNY 89,901,244.10, slightly improved from a net loss of CNY 91,288,036.03 in the previous period[147]. - The total comprehensive loss for the current period is CNY 86,189,402.94, compared to a loss of CNY 103,183,922.84 in the previous period[147]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,344,158,461.95, down 7.21% from ¥1,448,558,143.15 at the end of the previous year[16]. - The net assets attributable to shareholders decreased by 6.14% to ¥1,318,848,607.46 from ¥1,405,060,190.52 at the end of the previous year[16]. - Long-term equity investments decreased by 0.05% to 177.81 million yuan, while fixed assets decreased by 8.03% to 36.01 million yuan[30]. - The total liabilities decreased to CNY 39,083,660.17 from CNY 55,643,932.42, indicating a reduction of about 29.8%[138]. - The owner's equity totaled CNY 1,305,074,801.78, down from CNY 1,392,914,210.73, which is a decrease of approximately 6.3%[139]. - The total equity attributable to the parent company decreased to CNY 1,318,848,607.46 from CNY 1,405,060,190.52, a decline of approximately 6.1%[139]. Cash Flow - The net cash flow from operating activities improved to ¥14,964,890.71, a significant increase of 108.18% compared to -¥182,843,785.35 in the previous year[16]. - Total cash inflow from operating activities reached ¥150,386,370.75, up from ¥91,272,232.79 in the previous period, indicating a growth of approximately 64.8%[153]. - Cash outflow from operating activities decreased to ¥135,421,480.04 from ¥274,116,018.14, representing a reduction of about 50.7%[153]. - The net cash flow from investing activities improved to ¥57,526,395.77 from -¥49,956,216.89, marking a turnaround in investment performance[154]. - The cash and cash equivalents at the end of the period increased to ¥709,361,748.76 from ¥676,672,140.83, showing a growth of about 4.5%[154]. Business Operations - The company operates in five main areas: comprehensive management of medical insurance funds, health medical big data services, pharmaceutical benefit management services, third-party services for commercial health insurance, and medical artificial intelligence services[23]. - The company has developed a comprehensive management service platform for medical insurance funds, integrating existing services to provide a solution aimed at refined management of medical insurance funds[24]. - The DRGs payment settlement business has been successfully implemented in Jinhua and Liuzhou, recognized by all stakeholders, and is expected to be rolled out nationwide by 2020[26]. - The company has established a health big data service platform, connecting 40,000 medical institutions and 65,000 pharmacies, with an annual addition of nearly 800 million patient visits and 70 billion treatment data entries[27]. - The company has developed over 20 proprietary software products, including a smart management system for medical insurance funds, all of which have received copyright registration[38]. Strategic Initiatives - The company has launched the "1+1+N" health security service platform in Zhenjiang, which is expected to increase annual service fees from millions to tens of millions[46]. - The company is positioned to benefit from the new health insurance management policies, which are expected to enhance operational performance in the long term[44]. - The company is actively improving its employee structure and increasing talent recruitment to strengthen its R&D capabilities, which is crucial for sustainable development[46]. - The company plans to increase research and development investments to enhance platform optimization and maintain its competitive advantage in the health insurance service sector[66]. - The company is focusing on deepening and expanding its existing medical insurance fund management services, which will require substantial financial investment[67]. Corporate Governance and Compliance - The company does not plan to distribute cash dividends or issue bonus shares[5]. - The company has committed to providing accurate and complete information during its major asset sale process, ensuring compliance with relevant regulations[73]. - The company guarantees the authenticity, accuracy, and completeness of the information provided during the major asset sale, ensuring no false records or misleading statements exist[75]. - The company commits to timely disclose relevant information regarding the major asset sale in accordance with applicable laws and regulations[75]. - The company has undertaken measures to avoid any potential conflicts of interest or competition with Haihong Holdings post-transaction[77]. Shareholder Information - The total number of shares remains at 898,822,204, with 100% being unrestricted shares[117]. - The largest shareholder, Zhonghai Hengshi Industrial Development Co., Ltd., holds 25.74% of the shares, totaling 231,369,393 shares, with some shares pledged[120]. - The company reported a total of 10 major shareholders, with no strategic investors or general legal entities becoming part of the top 10 shareholders[120]. - The company has not reported any changes in limited sale shares during the reporting period[118]. - The company has not identified any related party relationships among the top 10 shareholders[120]. Legal and Regulatory Matters - There have been no criminal investigations or administrative penalties against the company or its executives in the last three years, ensuring a clean compliance record[79]. - The company has not conducted any major litigation or arbitration matters during the reporting period[90]. - The company has not experienced any penalties or rectification situations during the reporting period[90]. - The financial report for the half-year period has not been audited[88]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[93].